PIPELINE PREVIEWS

By No Comments
FDA Requires Follow-Up on TNF blocker Malignancy CasesThe FDA has announced that it is requiring that manufacturers of tumor necrosis factor (TNF) blockers perform enhanced safety surveillance in children, teenagers,…
Read More

CLINICAL TRIAL REVIEW

By No Comments
CUTANEOUS LUPUS ERYTHEMATOSUSA Randomized, Subject and Investigator-Blinded (Sponsor-Open), Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Multiple Ascending Doses of PD- 0360324 in Subjects with Active Cutaneous…
Read More